Surgical Treatment and Prognosis of Thymic Squamous Cell Carcinoma: A Retrospective Analysis of 105 Cases

Zhao, Yupei; Zhao, Heng; Hu, De Jin; Fan, Limin; Shi, Jianxin; Fang, Wentao

doi:10.1016/j.athoracsur.2013.04.078

Cited by 51 publications

(56 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As previously reported, complete resection was considered to be an important prognostic indicator for patients with thymic carcinoma [16,[22][23][24]. In the present study, 30 thymic carcinoma patients (61.2 %) underwent complete resection, and multivariate analysis indicated that complete resection was an independent prognostic factor [hazard ratio (HR), 14.97; 95 % confidence interval (CI), 3.72-60.20; P < 0.001).…”

Section: Discussionmentioning

confidence: 59%

“…Neoadjuvant chemotherapy was believed to improve the chance of complete resection in advanced thymic carcinoma [22]. In contrast to this study, however, Zhao et al revealed in a multivariate analysis that chemotherapy is a poor prognostic factor for disease-free survival [16]. Although the role of postoperative adjuvant therapies after complete resection of thymic carcinoma remains unclear, the prevailing belief in the field is that these therapies are effective in reducing local recurrence and distant metastasis [2,23].…”

Section: Discussionmentioning

confidence: 90%

“…Approximately 10-12 % of patients with MG have thymomas, whereas 30 % of thymomas are accompanied by MG [14,15]. Few studies report the coexistence of MG and thymic carcinoma, however, and the reported incidence varies dramatically, from 3.8 % to 32.5 % [2,4,16,17].…”

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses

Zhang

et al. 2015

Int J Clin Oncol

View full text Add to dashboard Cite

Masaoka stage (P = 0.048), and higher complete resection rates (P = 0.042). However, multivariate analysis demonstrated that complete resection was the only independent predictor for overall survival (OS) (P < 0.001).Conclusions The OS of patients with thymic carcinoma depends on complete resection, but patients with MG also demonstrate improved prognoses. MG patients have higher rates of complete surgical resection, which may account for their better prognoses. Patients with MG have unique features that may aid in the clinical management of these patients.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 90%

See 1 more Smart Citation

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses

Zhang

et al. 2015

Int J Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Metastatic thymic SCC has poor prognosis and usually requires multimodality treatment including surgery, radiation therapy, and chemotherapy. [4][5][6] Extrathoracic metastasis in patients with thymic carcinoma is very rare, around 3% to 6%. 5,7 In a review of 35 cases of extrathoracic thymic metastases, 7 only 2 cases demonstrated extrathoracic skeletal muscle metastases.…”

Section: Figurementioning

confidence: 99%

FDG PET/CT Manifestation of Rare Widespread Metastatic Chemoradiation-Refractory Thymic Squamous Cell Carcinoma

VanDreel

Patel

Emmadi

et al. 2015

Clinical Nuclear Medicine

View full text Add to dashboard Cite

A 74-year-old man underwent excisional biopsy of an anterior mediastinal mass that revealed squamous cell carcinoma of thymic origin. Immunohistochemistry revealed insulin-like growth factor-1 receptor positivity, which has been associated with worse prognosis. Restaging FDG PET/CT revealed extensive soft tissue and osseous metastases despite surgery and chemoradiation therapy. Patient was then enrolled in a clinical trial with anti-insulin-like growth factor-1 receptor therapy. A 3-month follow-up FDG PET/CT showed disease progression with an increase in size and number of hypermetabolic metastatic lesions, including interval development of multiple new metastases.

show abstract

“…It is difficult to detect these type of tumors in the early stage, since the symptoms of the disease are not remarkable until it invades or compromises other organs, including the heart, nerves, bronchus and blood vessels (2,3). The most favorable treatment is complete surgical resection (2,3); however, the majority of thymic carcinomas already invade into other organs and are metastasized when they are detected (4)(5)(6). For advanced and relapsed thymic carcinoma cases, no optimal chemotherapeutic drug or regimen exists.…”

Section: Introductionmentioning

confidence: 99%

Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma

et al. 2017

View full text Add to dashboard Cite

Abstract. Thymic carcinoma is a rare mediastinum malignant tumor derived from thymic epithelial cells. With the exception of complete resection, an effective therapy has not been established to date for advanced or relapsed thymic carcinoma. The present study examined the protein expression of excision repair cross-complementation group 1 (ERCC1) and class Ⅲ β-tubulin (TUBB3), which are consider to be indicators of the anticancer activity of platinum-based and taxane-based chemotherapy, respectively. The expression of ERCC1 and TUBB3 proteins was examined in 40 thymic carcinoma patients who underwent either surgical resection or core-needle biopsy. The present study investigated whether the expression of ERCC1 and TUBB3 proteins was associated with the overall survival and clinicopathological factors of thymic carcinoma patients. The expression of ERCC1 and TUBB3 proteins was also evaluated in 50 patients who underwent curative resection for non-small cell lung cancer (NSCLC). The expression of ERCC1 and TUBB3 proteins was positive in 8 cases (20%) among the thymic carcinoma patients. ERCC1 was expressed in 21 cases (42%), while TUBB3 was expressed in 27 cases (54%), among the 50 NSCLC patients evaluated in the present study. Only complete resection was observed to be associated with a better prognosis than incomplete resection (P=0.0341). Other clinicopathological factors, including expression of ERCC1 and TUBB3 proteins, exhibited no effect on overall survival. The expression of ERCC1 and TUBB3 proteins in the thymic carcinoma cases was lower than that in the NSCLC cases. The present results suggest a possibility for better antitumor effects of platinum-based and taxane-based chemotherapy on thymic carcinoma patients.

show abstract

Surgical Treatment and Prognosis of Thymic Squamous Cell Carcinoma: A Retrospective Analysis of 105 Cases

Cited by 51 publications

References 14 publications

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses

Thymic carcinoma patients with myasthenia gravis exhibit better prognoses

FDG PET/CT Manifestation of Rare Widespread Metastatic Chemoradiation-Refractory Thymic Squamous Cell Carcinoma

Expression of excision repair cross-complementation group 1 and class III β-tubulin in thymic carcinoma

Contact Info

Product

Resources

About